Stocktoria
IQVIA HOLDINGS INC. IQV
IQVIA HOLDINGS INC. (IQV) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the grey zone. It pays a dividend yielding 1.78% (safety: no dividend). FY2025 revenue was $16.3B at a 8.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-07-29 | JP Morgan | Overweight (main) |
| 2026-07-29 | Stifel | Buy (main) |
| 2026-07-29 | TD Cowen | Buy (main) |
| 2026-07-29 | RBC Capital | Outperform (main) |
| 2026-07-29 | BMO Capital | Outperform (main) |
| 2026-07-29 | Baird | Outperform (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | -0.07 |
| Retained earnings / assets | 0.248 |
| EBIT / assets | 0.073 |
| Equity / liabilities | 0.284 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| IQV | IQVIA HOLDINGS INC. | 5/9 | 1.14 | 23.5 | +5.9% |
| ICLR | ICON PLC | 6/9 | 2.1 | 56.7 | +0.8% |
| INCY | INCYTE CORP | 6/9 | 7.9 | 17.7 | +21.2% |
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | 4/9 | 1.81 | — | -0.9% |
| MEDP | Medpace Holdings, Inc. | 6/9 | 0.2 | 33.4 | +20% |
| NRC | NRC HEALTH | 3/9 | 0.03 | — | -4% |
| OABI | OmniAb, Inc. | 1/9 | 6 | — | -29.3% |
About IQVIA HOLDINGS INC.
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
FAQ
Is IQV financially healthy?
IQVIA HOLDINGS INC.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does IQV pay a dividend, and is it safe?
Yes. IQVIA HOLDINGS INC. pays a dividend yielding about 1.78% with a None payout ratio, rated “no dividend” for safety.
How profitable is IQV?
In FY2025, IQVIA HOLDINGS INC. had a net margin of 8.3% and a return on equity of 20.5%.
Is IQV overvalued or undervalued?
IQVIA HOLDINGS INC. trades at about 30.8× trailing earnings — below its 10-year norm (10-year range 17.8×–167.0×, median 49.5×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for IQV?
The average Wall-Street price target for IQVIA HOLDINGS INC. is $275.17, about 13.8% above the recent price, from 18 analysts (consensus: strong buy).
Is IQV a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on IQVIA HOLDINGS INC.: a Piotroski F-score of 5/9, an Altman Z″ in the grey zone, a P/E of about 23.5×, a dividend yield of 1.78%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.